Made into a permanent programme in 2009, it set out to sequence the
genomes of potential bioterror agents,
explore new drug technologies and develop «broad - spectrum» therapies that would work against multiple
bacterial and viral pathogens — especially haemorrhagic fever viruses such as Ebola and Marburg.